20 completed. 20 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 20 |
| Phase 2 | 6 | Completed 6 |
Follow Eczema: new trials by email Literature Review of Eczema trials Research Report on Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus ATTO-1310, ATTO-1310 Placebo - Normal Volunteers, Atopic Dermatitis (AD) | Phase 1 | Completed | Attovia Therapeutics Inc | 108 | 2025-01-14 | 2026-09-11 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis BMS-986326, Placebo - Dermatitis, Atopic | Phase 1 | Completed | Bristol-Myers Squibb | 64 | 2024-03-06 | 2025-12-08 |
| A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants Rocatinlimab - Atopic Dermatitis | Phase 1 | Completed | Amgen | 20 | 2024-01-23 | 2026-01-07 |
| Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% Fexofenadine Hydrochloride Topical Lotion 1% (OP2101) - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 1 | Completed | OrchestratePharma GmbH | 12 | 2022-04-01 | 2023-03-29 |
| Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema ARQ-151 cream 0.15%, ARQ-151 cream 0.05% - Atopic Dermatitis (Eczema) | Phase 1 | Completed | Arcutis Biotherapeutics, Inc. | 101 | 2019-12-23 | 2023-07-24 |
| A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants PF-07038124 and Vehicle, PF-07038124 or vehicle - Dermatitis Atopic | Phase 1 | Completed | Pfizer | 34 | 2019-10-29 | 2020-05-14 |
| Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult Natural Treatment - Dermatitis, Seborrheic, Dry Skin; Eczema | Phase 1 / Phase 2 | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 77 | 2019-07-08 | 2025-02-24 |
| A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis Experimental: B244 - Eczema, Atopic Dermatitis | Phase 1 | Completed | AOBiome LLC | 28 | 2018-12-07 | 2024-08-05 |
| A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis ASN002, Placebo Oral Tablet - Dermatitis, Atopic, Dermatitis Eczema | Phase 1 | Completed | Asana BioSciences | 36 | 2017-04-12 | 2023-05-10 |
| A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis HAT01H Cream, Vehicle Cream - Atopic Dermatitis, Eczema | Phase 1 / Phase 2 | Completed | Haus Bioceuticals | 30 | 2017-03-26 | 2018-11-07 |
| A 47 Hour Occlusive Cutaneous Skin Patch Test on Adult Subjects With Dry/Atopic Skin Eczema Repair Emollient - Eczema | Phase 1 | Completed | Reckitt Benckiser Healthcare (UK) Limited | 33 | 2016-04-01 | 2016-06-03 |
| Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis HAT1 topical cream, Vehicle cream - Dermatitis, Atopic | Phase 1 / Phase 2 | Completed | Haus Bioceuticals | 48 | 2016-02-29 | 2017-02-23 |
| An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P - Dermatitis, Atopic | Phase 1 / Phase 2 | Completed | Vitae Pharmaceuticals, Inc. | 104 | 2015-12-15 | 2019-02-15 |
| Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) Dupilumab, Midazolam, Omeprazole - Atopic Dermatitis | Phase 1 | Completed | Regeneron Pharmaceuticals | 14 | 2015-12-01 | 2016-08-22 |
| A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD) Pimecrolimus cream, Betamethasone dipropionate cream, Clobetasol propionate cream - Atopic Dermatitis | Phase 1 | Completed | LEO Pharma | 30 | 2015-02-01 | 2025-02-24 |
| DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study DEC033 Study Product - Eczema | Phase 1 | Completed | Medicus Research, LLC | 20 | 2014-01-01 | 2015-03-05 |
| A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis OPA-15406, Tacrolimus, Placebo - Atopic Dermatitis | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 92 | 2012-08-01 | 2014-01-17 |
| A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment - Healthy Volunteers, Atopic Dermatitis | Phase 1 | Completed | Novartis Pharmaceuticals | 12 | 2011-05-01 | 2020-12-08 |
| Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis MRX-6, Steroid - Allergic Contact Dermatitis | Phase 1 / Phase 2 | Completed | Hadassah Medical Organization | 13 | 2011-03-01 | 2015-04-21 |
| Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis NF-kappaB Decoy - Atopic Dermatitis | Phase 1 / Phase 2 | Completed | Anesiva, Inc. | 75 | 2005-03-01 | 2008-11-19 |
Dermatitis, Atopic (16) · Dermatitis (2) · Pruritus (2) · Chronic Urticaria (1) · Dermatitis, Allergic Contact (1) · Dermatitis, Contact (1) · Dermatitis, Seborrheic (1) · Exanthema (1) · Netherton Syndrome (1) · Psoriasis (1) · Skin Diseases (1) · Skin Diseases, Eczematous (1) · Skin Diseases, Genetic (1) · Urticaria (1)
Skin and Connective Tissue Diseases (20) · Skin Diseases (19) · Skin Diseases, Eczematous (19) · Dermatitis (18) · Hypersensitivity (17) · Immune System Diseases (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Genetic Diseases, Inborn (16) · Hypersensitivity, Immediate (16) · Skin Diseases, Genetic (15) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Skin Diseases, Papulosquamous (2) · Skin Manifestations (2) · Abnormalities, Multiple (1)
Caffeine (1) · Clobetasol (1) · Metoprolol (1) · Midazolam (1) · NF-kappaB decoy (1) · Omeprazole (1) · Steroids (1) · Tacrolimus (1) · Warfarin (1) · betamethasone-17,21-dipropionate (1) · difamilast (1) · dupilumab (1) · gusacitinib (1) · pimecrolimus (1)
Haus Bioceuticals (2) · AOBiome LLC (1) · Amgen (1) · Anesiva, Inc. (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Arcutis Biotherapeutics, Inc. (1) · Asana BioSciences (1) · Attovia Therapeutics Inc (1) · Bristol-Myers Squibb (1) · Hadassah Medical Organization (1) · LEO Pharma (1) · Medicus Research, LLC (1) · Novartis Pharmaceuticals (1) · OrchestratePharma GmbH (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1)
United States (11) · Canada (4) · Germany (2) · Israel (2) · Bangladesh (1) · China (1) · Czechia (1) · France (1) · India (1) · Netherlands (1) · Poland (1) · Spain (1)
Andria Langenberg, MD (1) · Christy Harutunian (1) · David Berk, MD (1) · David Zammit, Ph.D. (1) · Emma Guttmann, MD (1) · Eric Sicard, MD (1) · Judith Ng-Cashin, MD (1) · Lucy Bilaver, PHD (1) · Mukta Sachdev, MD (1)